Hal Martin

3.4k citations
44 papers · 1.9k · h-index 21

Impact in

  • Virology top 1%
    • HIV Research and Treatment
  • Infectious Diseases top 1%
    • HIV/AIDS drug development and treatment
    • HIV/AIDS Research and Interventions

Papers in

  • Infectious Diseases 37
    • HIV/AIDS drug development and treatment 36
    • HIV/AIDS Research and Interventions 7
  • Virology 10
    • HIV Research and Treatment 10
Co-authors
Erin Quirk (16 shared papers)Xuelian Wei (9 shared papers)Andrew Cheng (9 shared papers)Kirsten White (14 shared papers)Indira Brar (6 shared papers)Joseph M. Custodio (6 shared papers)Paul E. Sax (9 shared papers)Anthony Mills (5 shared papers)
Journals
Open Forum Infectious Diseases (9 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (8 papers)The Lancet HIV (6 papers)AIDS (3 papers)Sexually Transmitted Infections (2 papers)
Partner nations
United StatesFranceUnited Kingdom

In The Last Decade

Hal Martin

42 papers receiving 1.8k citations

Peers

Hal Martin
Comparison fields: 5 of 53
  • Virology 557
  • Infectious Diseases 1.4k
  • Emergency Medicine 526
  • Hepatology 71
  • Epidemiology 163
Replace Donnie McGrath with:
Donnie McGrath United States
Dan Duiculescu Romania
Joseph J. Eron United States
Cheryl McDonald United States
Manuela Colafigli Italy
Antonio Antela Spain
Michael Aboud United Kingdom
Marita Stevens Belgium
Frank Tomaka United States
Arkaitz Imaz Spain
Hal Martin relative to Donnie McGrath United States Donnie McGrath's profile →
Citations per field
00.5×10×20×27.8×
Donnie McGrath · 1×
Citations per year

Countries citing papers authored by Hal Martin

Since Specialization
Citations

This map shows the geographic impact of Hal Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hal Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hal Martin more than expected).

Fields of papers citing papers by Hal Martin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hal Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hal Martin. The network helps show where Hal Martin may publish in the future.

Co-authors

The 25 scholars most cited alongside Hal Martin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hal Martin Line = papers co-authored together Hal Martin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
The Lancet ·Joel E. Gallant, Adriano Lazzarin, Anthony Mills, Chloe Orkin, Daniel Podzamczer, Pablo Tebas, Pierre-Marie Girard, Indira Brar, Eric S. Daar, David A. Wohl, Jürgen K. Rockstroh, Xuelian Wei, Joseph M. Custodio, Kirsten White, Hal Martin, Andrew Cheng, Erin Quirk
2017268
2
Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Paul E. Sax, Andrew Zolopa, Indira Brar, Richard Elion, Roberto Ortiz, Frank A. Post, Hui Wang, Christian Callebaut, Hal Martin, Marshall W. Fordyce, Scott McCallister
2014173
3
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
The Lancet HIV ·Jean‐Michel Molina, Douglas Ward, Indira Brar, Anthony Mills, Hans‐Jürgen Stellbrink, Luís F. López‐Cortés, Peter Ruane, Daniel Podzamczer, Cynthia Brinson, Joseph M. Custodio, Hui Liu, Kristen Andreatta, Hal Martin, Andrew Cheng, Erin Quirk
2018144
4
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anthony Mills, Gordon Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, Anita Scribner, David Shamblaw, Michael S. Saag, Huyen Cao, Hal Martin, Moupali Das, Anne Thomas, Hui C. Liu, Mingjin Yan, Christian Callebaut, Joseph M. Custodio, Andrew Cheng, Scott McCallister
2015127
5
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
The Lancet HIV ·David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie Thompson, Cynthia Brinson, Debbie Hagins, Moti Ramgopal, Andrea Antinori, Xuelian Wei, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin
2019121
6
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
The Lancet HIV ·Eric S. Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Catherine Creticos, Jürgen K. Rockstroh, Jean‐Michel Molina, Ellen Koenig, Ya-Pei Liu, Joseph M. Custodio, Kristen Andreatta, Hiba Graham, Andrew Cheng, Hal Martin, Erin Quirk
2018121
7
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
The Lancet HIV ·Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens, Helmut Albrecht, Paul E. Sax, Franco Maggiolo, Catherine Creticos, Claudia Martorell, Xuelian Wei, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin
2019101
8
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus
Clinical Infectious Diseases ·Paul E. Sax, Jürgen K. Rockstroh, Anne F. Luetkemeyer, Yazdan Yazdanpanah, Douglas Ward, Benoît Trottier, Armin Rieger, Hui Liu, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin, (unknown)
202084
9
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials
Clinical Infectious Diseases ·Kristine M. Erlandson, Christoph C Carter, Kathleen Melbourne, Todd T. Brown, Cal Cohen, Moupali Das, Stefan Eßer, Hailin Huang, John R. Koethe, Hal Martin, Grace A. McComsey, Chloe Orkin, Frank A. Post, Jürgen K. Rockstroh, Paul E. Sax, Hans‐Jürgen Stellbrink, Laura Waters, Xuelian Wei, Jordan E. Lake
202181
10
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joel E. Gallant, Melanie Thompson, Edwin DeJesus, Gene W. Voskuhl, Xuelian Wei, Heather Zhang, Kirsten White, Andrew Cheng, Erin Quirk, Hal Martin
201779
11
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
The Lancet HIV ·Paul E. Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, Julie Péloquin, Xuelian Wei, Kirsten White, Andrew Cheng, Hal Martin, Erin Quirk
201772
12
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
Journal of Antimicrobial Chemotherapy ·Kristen Andreatta, Madeleine Willkom, Ross Martin, Silvia Chang, Lilian Wei, Hui Liu, Ya-Pei Liu, Hiba Graham, Erin Quirk, Hal Martin, Kirsten White
201950
13
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Natalya Gankina, Vadim Pokrovsky, Evgeny Voronin, Jeffrey L. Stephens, Edwin DeJesus, Hui Wang, Rima Acosta, Huyen Cao, Erin Quirk, Hal Martin, Tariro Makadzange
201946
14
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine
Patient ·David A. Wohl, Amanda Clarke, Franco Maggiolo, Will Garner, Marianne Laouri, Hal Martin, Erin Quirk
201843
15
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Infectious Diseases and Therapy ·(unknown), Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido, Stéphane De Wit, Linos Vandekerckhove, Juan Berenguer, Michelle L. D’Antoni, Christiana Blair, Susan K. Chuck, David Piontkowsky, Hal Martin, Richard Haubrich, Ian R. McNicholl, Joel E. Gallant
202142
16
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks
Antimicrobial Agents and Chemotherapy ·Rima Acosta, Madeleine Willkom, Ross Martin, Silvia Chang, Xuelian Wei, William Garner, Justin Lutz, Sophia R. Majeed, Devi SenGupta, Hal Martin, Erin Quirk, Kirsten White
201941
17
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
The Lancet HIV ·Anchalee Avihingsanon, Hongzhou Lu, Chee Loon Leong, Chien‐Ching Hung, Ellen Koenig, Sasisopin Kiertiburanakul, Man‐Po Lee, Khuanchai Supparatpinyo, Fujie Zhang, Sophia Rahman, Michelle L. D’Antoni, Hongyuan Wang, Jason T. Hindman, Hal Martin, Jared M. Baeten, Taisheng Li
202334
18
Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight
PLoS ONE ·Carrie McMahon, James L. Trevaskis, Christoph C Carter, Kevin Holsapple, Kirsten White, Moupali Das, Sean E Collins, Hal Martin, Leigh Ann Burns‐Naas
202032
19
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Debbie Hagins, Princy Kumar, Michael S. Saag, Anson K Wurapa, Indira Brar, Daniel Berger, Olayemi Osiyemi, Corrilynn O. Hileman, Moti Ramgopal, Cheryl McDonald, Christiana Blair, Kristen Andreatta, Sean E Collins, Diana M. Brainard, Hal Martin, (unknown)
202130
20
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age
HIV Medicine ·Franco Maggiolo, Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido, (unknown), Linos Vandekerckhove, Juan Berenguer, Michelle L. D’Antoni, Christiana Blair, Susan K. Chuck, David Piontkowsky, Hal Martin, Richard Haubrich, Ian R. McNicholl, Joel E. Gallant
202228

About Hal Martin

Hal Martin is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Pediatrics, Perinatology and Child Health and Genetics, having authored 44 papers that have together received 1.9k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (36 papers), HIV Research and Treatment (10 papers), HIV-related health complications and treatments (8 papers), HIV/AIDS Research and Interventions (7 papers), Pharmacological Effects and Toxicity Studies (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), Hepatitis C virus research (2 papers) and Diabetes Treatment and Management (2 papers). The work is most often cited by research in Virology (557 citations), Infectious Diseases (1.4k citations), Emergency Medicine (526 citations), Hepatology (71 citations) and Epidemiology (163 citations). Hal Martin has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Erin Quirk, Xuelian Wei, Andrew Cheng, Kirsten White, Indira Brar, Joseph M. Custodio, Paul E. Sax, Anthony Mills, Jürgen K. Rockstroh and Sean E Collins. Their work appears in journals such as Open Forum Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes, The Lancet HIV, AIDS and Sexually Transmitted Infections.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donnie McGrathBreakdown of academic impact, for papers by Dan DuiculescuBreakdown of academic impact, for papers by Joseph J. EronBreakdown of academic impact, for papers by Cheryl McDonaldBreakdown of academic impact, for papers by Manuela ColafigliBreakdown of academic impact, for papers by Antonio AntelaBreakdown of academic impact, for papers by Michael AboudBreakdown of academic impact, for papers by Marita StevensBreakdown of academic impact, for papers by Frank TomakaBreakdown of academic impact, for papers by Arkaitz Imaz